Xvivo Perfusion AB
STO:XVIVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xvivo Perfusion AB
STO:XVIVO
|
SE |
|
S
|
Shaanxi Sirui Advanced Materials Co Ltd
SSE:688102
|
CN |
|
A
|
Axion Ventures Inc
F:2A5
|
CA |
|
I
|
IMS SA
WSE:IMS
|
PL |
|
Faze Three Ltd
NSE:FAZE3Q
|
IN |
|
IGEA Pharma NV
F:3B5
|
NL |
Wall Street
Price Targets
XVIVO Price Targets Summary
Xvivo Perfusion AB
According to Wall Street analysts, the average 1-year price target for
XVIVO
is 316.2 SEK
with a low forecast of 247.45 SEK and a high forecast of 404.25 SEK.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is XVIVO's stock price target?
Price Target
316.2
SEK
According to Wall Street analysts, the average 1-year price target for
XVIVO
is 316.2 SEK
with a low forecast of 247.45 SEK and a high forecast of 404.25 SEK.
What is Xvivo Perfusion AB's Revenue forecast?
Projected CAGR
27%
For the last 12 years the
compound annual growth rate for
Xvivo Perfusion AB's revenue is
23%.
The projected
CAGR
for the next 3 years is
27%.
What is Xvivo Perfusion AB's Operating Income forecast?
Projected CAGR
62%
For the last 12 years the
compound annual growth rate for
Xvivo Perfusion AB's operating income is
20%.
The projected
CAGR
for the next 3 years is
62%.
What is Xvivo Perfusion AB's Net Income forecast?
Projected CAGR
131%
For the last 12 years the
compound annual growth rate for
Xvivo Perfusion AB's net income is
10%.
The projected
CAGR
for the next 3 years is
131%.
